You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms will evaluate Stratafide, a pan-solid tumor diagnostic test designed to identify actionable genomic alterations in tissue or blood samples.
In PNAS this week: role for MEN1 in pancreatic stress response, analysis of B immune cell response to yellow fever vaccine, and more.
In PNAS this week: 10-SNP polygenic risk score for papillary thyroid cancer performs as well as a larger one, loss-of-function mutation affecting voltage-gated sodium channel, and more.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
The Parsippany, New Jersey-based firm expects to expand relationships with multiple biopharmaceutical companies after bolstering its biopharma services business.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.
Under the new 15-year exclusive agreement, the test will become available through all of Sonic's clinical labs and anatomic pathology practices in the US.
When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.